Previous 10 | Next 10 |
Nurix Therapeutics ( NASDAQ: NRIX ) on Thursday said the U.S. FDA had approved its investigational new drug application to expand its ongoing phase 1 trial of its inhibitor NX-1607 into sites in the U.S. NX-1607 is being evaluated in multiple immuno-oncology indication...
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients in U.K. with plans to expand to clinical sites in the U.S. SAN FRANCISCO, June 30, 2022 (GLOBE NEWSWIRE) -- Nurix Ther...
SAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-...
Gainers: Rent the Runway (RENT) +10%. BioAtla (BCAB) +9%. Adaptive Biotechnologies Corporation (ADPT) +5%. Accolade (ACCD) +5%. Nurix Therapeutics (NRIX) +5%. Losers: DocuSign (DOCU) -23%. Stitch Fix (SFIX) -16%. Comtech Telecommunications (CMTL) -15%. View (VIEW) -12%. DBV Te...
SAN FRANCISCO, June 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for three of its w...
Gainers: Okta (OKTA) +14%. StoneCo (STNE) +9%. Nurix Therapeutics (NRIX) +5%. Protagonist Therapeutics (PTGX) +5%. MacroGenics (MGNX) +5%. Losers: HashiCorp (HCP) -9%. JOANN (JOAN) -8%. Instil Bio (TIL) -5%. Magnite (MGNI) -5%. Zumiez (ZUMZ) -4%. For further details se...
Wells Fargo has upgraded Nurix Pharmaceuticals (NASDAQ:NRIX) to overweight from equal weight citing the potential of NX-2127 in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). Shares are up 12% in Tuesday morning trading. The firm established a price target of $...
Gainers: TherapeuticsMD (TXMD) +355%. MoonLake Immunotherapeutics (MLTX) +24%. Gritstone bio (GRTS) +18%. Nurix Therapeutics (NRIX) +10%. DexCom (DXCM) +9%. Losers: Outlook Therapeutics (OTLK) -54%. Elevation Oncology (ELEV) -18%. SIGA Technologies (SIGA) -1...
Gainers: Redbox Entertainment (RDBX) +37%. Vivid Seats (SEAT) +37%. VIQ Solutions (VQS) +29%. Modine Manufacturing (MOD) +28%. Eargo (EAR) +27%. Charah Solutions (CHRA) +23%. Baozun (BZUN) +21%. Alpha Teknova (TKNO) +20%. Standard BioTools (LAB) +20%. Losers: NRx Pharmaceuticals (NRXP) -63%. ...
Nurix Therapeutics (NASDAQ:NRIX) has recorded its worst-ever intraday decline after the company held its research & development (R&D) day on Thursday following a positive update from its ongoing Phase 1 trial for the cancer candidate NX-2127. Before the market opened, Nurix (NRIX) ann...
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...